We are delighted to share that the first ever EB specific treatment is one step closer to bedside in Europe.Read More
News and Stories: Research
Some pain isn’t easy to see. Alison Hyland will be the first to tell you that her EB isn’t as severe as what other people live with.Read More
UCD researchers developing ‘life changing’ treatment for painful skin condition
UNIVERSITY COLLEGE DUBLIN researchers are developing a new therapy which could potentially transform the lives of people with the painful skin disease, EB.Read More
DEBRA International research community
In 2019, DEBRA Ireland, DEBRA UK and DEBRA Austria funded a Consensus Conference, bringing EB experts from various parts of the world together to reclassify disorders with skin fragility, focusing on EB.Read More
First ever successful Phase III clinical study for a potential wound healing product for EB
Some good news for EB research – Amryt announces positive top line results from pivotal Phase 3 ‘EASE’ trial of FILSUVEZ® in epidermolysis bullosa.Read More
Funding Research through DEBRA International to advance potential treatments for EB
DEBRA International has played a vital role over the years in progressing research into treatments and cures for EB. We recently published a Research Impact Report to show the fantastic work being done through DEBRA International.Read More
DEBRA International Research Impact Report
DEBRA Ireland has a long history of driving and supporting research with the potential to improve the lives of people living with EB.Read More
International Women’s Day
We want to take time out to celebrate all the incredible women involved in fighting for those living with EB.
Rare Disease Day 2020
Rare shouldn’t mean…Ignored…Forgotten…Set aside…Abandoned.
Rare Disease Day takes place on the last day of February each year. But rare disease isn’t just a day. For the 300 million people worldwide living with rare disease, 500,000 of which live with EB, it’s every day. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.